New hope for HER2 cancers: first human trial launches

NCT ID NCT05523947

Recruiting now Disease control Sponsor: Yuhan Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This early-phase trial tests an experimental drug called YH32367 in people with HER2-positive solid tumors that have spread or cannot be removed by surgery. The study has two parts: first, finding a safe dose, then testing that dose in specific cancer types like biliary tract cancer. About 147 participants will be enrolled to check safety, how the drug moves through the body, and whether it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YH32367 (an experimental drug)
What this could lead to: If successful, this could point toward a new treatment option for people with HER2-positive cancers that have stopped responding to standard therapies.
What could go wrong: This is a very early first-in-human study, so safety and effectiveness are not yet known. The drug may not shrink tumors or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms breast neoplasm gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE SOLID TUMOR

Contacts and locations

Locations

Ajou University Hospital
RECRUITING

Suwon, Gyeonggi-do, 16499, South Korea
Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Austin Health
WITHDRAWN

Melbourne, Australia
Blacktown Hospital
RECRUITING

Sydney, Australia
Breast Cancer Research Centre - WA
WITHDRAWN

Perth, Australia
CHA Bundang Medical Center
RECRUITING

Seongnam-si, Gyeonggi-do, 13496, South Korea
Catholic University of Korea St. Vincent's Hospital
RECRUITING

Suwon, Gyeonggi-do, 16247, South Korea
Chungbuk National University Hospital
RECRUITING

Cheongju-si, North Chungcheong, 28644, South Korea
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Gachon Gil University Medical Center
RECRUITING

Incheon, 21565, South Korea
Gyeongsang National University Hospital
RECRUITING

Jinju, Gyeongsangnam-do, 52727, South Korea
Korea University Anam Hospital
RECRUITING

Seoul, 02841, South Korea
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea
Southern Oncology Clinical Research Unit
TERMINATED

Adelaide, Australia
The Catholic University of Korea, St. Mary's hospital
RECRUITING

Seoul, 06591, South Korea
Ulsan University Hospital
RECRUITING

Ulsan, 44437, South Korea
Vanderbilt Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.